A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
Latest Information Update: 08 May 2025
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Il-Yang Pharmaceutical
Most Recent Events
- 30 Apr 2025 Status changed from active, no longer recruiting to completed.
- 30 Oct 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Jun 2024 New trial record